3,391 Shares in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Purchased by Aurora Investment Counsel

Aurora Investment Counsel acquired a new position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 3,391 shares of the biopharmaceutical company’s stock, valued at approximately $1,392,000.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Capital Financial Planning LLC bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $33,000. Landsberg Bennett & Dubbaneh LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 13.5% in the first quarter. Landsberg Bennett & Dubbaneh LLC now owns 815 shares of the biopharmaceutical company’s stock worth $332,000 after buying an additional 97 shares during the period. Nordea Investment Management AB boosted its holdings in shares of Regeneron Pharmaceuticals by 1.5% in the third quarter. Nordea Investment Management AB now owns 4,215 shares of the biopharmaceutical company’s stock worth $1,703,000 after buying an additional 64 shares during the period. Morgan Stanley boosted its holdings in shares of Regeneron Pharmaceuticals by 70.6% in the third quarter. Morgan Stanley now owns 464,603 shares of the biopharmaceutical company’s stock worth $187,719,000 after buying an additional 192,236 shares during the period. Finally, Meeder Asset Management Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 59.8% in the fourth quarter. Meeder Asset Management Inc. now owns 12,975 shares of the biopharmaceutical company’s stock worth $4,846,000 after buying an additional 4,858 shares during the period. 66.38% of the stock is currently owned by institutional investors and hedge funds.

Several brokerages have commented on REGN. Morgan Stanley decreased their target price on shares of Regeneron Pharmaceuticals from $420.00 to $389.00 and set an “equal weight” rating for the company in a report on Wednesday. Jefferies Financial Group decreased their target price on shares of Regeneron Pharmaceuticals from $376.00 to $343.00 and set a “hold” rating for the company in a report on Wednesday, April 17th. Canaccord Genuity reiterated a “hold” rating and issued a $353.00 target price (down from $408.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday. BMO Capital Markets reduced their price target on shares of Regeneron Pharmaceuticals from $412.00 to $375.00 and set a “market perform” rating for the company in a research report on Wednesday. Finally, BidaskClub lowered shares of Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, April 25th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Regeneron Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $407.13.

REGN traded down $11.31 during midday trading on Friday, hitting $312.86. 1,402,867 shares of the company’s stock traded hands, compared to its average volume of 987,546. The firm has a market cap of $35.42 billion, a PE ratio of 15.80, a PEG ratio of 1.39 and a beta of 1.08. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.67 and a current ratio of 4.58. Regeneron Pharmaceuticals Inc has a one year low of $290.44 and a one year high of $442.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported $4.45 EPS for the quarter, missing the Zacks’ consensus estimate of $5.24 by ($0.79). Regeneron Pharmaceuticals had a net margin of 35.13% and a return on equity of 26.95%. The firm had revenue of $1.71 billion during the quarter, compared to the consensus estimate of $1.76 billion. During the same period in the prior year, the business earned $4.67 EPS. The company’s revenue for the quarter was up 13.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals Inc will post 19.92 earnings per share for the current fiscal year.

In other news, major shareholder Sanofi sold 131,115 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $412.17, for a total value of $54,041,669.55. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 12.42% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “3,391 Shares in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Purchased by Aurora Investment Counsel” was originally published by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.baseballdailydigest.com/news/2019/05/11/3391-shares-in-regeneron-pharmaceuticals-inc-regn-acquired-by-aurora-investment-counsel.html.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Further Reading: Net Margin – Understanding the Different Kinds of Profit

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.